海思(si)科午(wu)間發(fa)布公(gong)(gong)告，公(gong)(gong)司獲(huo)得注(zhu)(zhu)射(she)用(yong)(yong)艾(ai)司奧(ao)美拉唑鈉藥品注(zhu)(zhu)冊(ce)批件，公(gong)(gong)司該品種商標(biao)名為“海思(si)汀®”，適應癥為用(yong)(yong)于作為當(dang)口服療法(fa)不適用(yong)(yong)時，胃(wei)食管(guan)反流病的(de)替代療法(fa)；用(yong)(yong)于口服療法(fa)不適用(yong)(yong)的(de)急性胃(wei)或(huo)十二指(zhi)腸潰瘍(yang)出(chu)血(xue)的(de)低危患者。截至目(mu)前，公(gong)(gong)司在注(zhu)(zhu)射(she)用(yong)(yong)艾(ai)司奧(ao)美拉唑鈉研(yan)發(fa)項目(mu)上(shang)已(yi)投入研(yan)發(fa)費用(yong)(yong)共計613萬元。（每日經濟新(xin)聞）